SciBase Moves to Strengthen Position with SEK 58 Million Rights Issue Strategy

In an important move to enhance its market position, SciBase Holding AB (publ) has announced plans to carry out a rights issue aimed at raising approximately SEK 57.5 million prior to transaction costs. This strategic decision follows the authorization granted by the annual general meeting held on May 19, 2026. The funding generated from this rights issue is intended to support the company’s ongoing commercialisation efforts, particularly in the lucrative US market, where it has seen substantial growth recently.

On September 10, 2026, shareholders will receive one subscription right for each share held, allowing them the opportunity to subscribe for three new shares at the price of SEK 15 each, starting from the subscription period set between September 15 and September 29, 2026. Given the increasing interest, many existing shareholders and entities, including Ribbskottet AB and Castle Biosciences Inc, have committed a significant SEK 33.3 million, highlighting robust investor confidence in SciBase’s initiatives. Furthermore, Bergs Securities AB has expressed intentions to guarantee around SEK 24.2 million of the rights issue, showcasing strong institutional support.

As reflected in SciBase's financial performance, the company has reported remarkable growth, with a striking 68% increase in revenues to SEK 29.6 million during the first half of 2026, in a large part fueled by heightened sales in the US, particularly in melanoma diagnostics. This surge in revenue reflects a 79% increase in US melanoma diagnostics sales alone, underscoring the firm’s successful entry and expansion within the competitive diagnostic market.

SciBase is especially dedicated to leveraging its platform, Nevisense, which employs AI and Electrical Impedance Spectroscopy (EIS) to enhance diagnostic accuracy in dermatology. This technology is pivotal for the early detection and prevention of skin conditions, including melanoma, and is expected to play a central role as the company targets reimbursement authorization from US regulatory bodies by early 2027, which will be crucial for sustained growth.

The collaboration with Castle Biosciences reflects another strategic move to bolster SciBase’s product offering. By joining forces, they aim to improve the diagnostic processes for a range of skin diseases, including atopic dermatitis. This partnership not only broadens SciBase’s portfolio but also taps into the potential of the US market, aligning with the company’s strategic direction. The anticipated outcomes from this collaboration could unlock significant market potential, allowing SciBase to position itself robustly across multiple dermatology segments.

Pia Renaudin, CEO of SciBase, articulates enthusiasm about the current moment for the company, emphasizing how the collaboration and ongoing developments can lead to fulfilling critical commercial milestones. Renaudin notes that SciBase's groundwork has equipped the company to respond effectively to market demands, especially with focus directed towards the US market.

Moreover, SciBase’s Board Chairman, Jesper Høiland, reflects on the upper management transition with an uninterrupted focus on strengthening the established operational framework while pursuing the appointment of a new CEO. This forthcoming leadership will be instrumental in steering SciBase through an exciting phase of commercial expansion and operational management, ensuring that the foundation laid can lead to significant long-term benefits.

To capitalize on its current momentum, this rights issue is a calculated initiative aimed at ensuring the company can seize growth opportunities in both melanoma and broader skin condition diagnostics. The company’s robust financial strategies, underscored by institutional investor backing and positive sales trends, position SciBase favorably in an evolving marketplace.

In conclusion, the SEK 58 million rights issue not only marks a pivotal step for SciBase but also encapsulates the company’s ambition to emerge as a leader in the diagnostic dermatology field. As SciBase prepares for an exciting future, all eyes will be on how effectively it navigates its planned initiatives and harnesses emerging market opportunities.